跳至主要内容
临床试验/NCT02037165
NCT02037165已完成1 期

Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB (Ultraviolet)-Irradiated Skin in Healthy Male Volunteers (a Single-blinded, Randomised, Placebo-controlled, Single-dose, Five-way Crossover Study)

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2014年1月21日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
25
试验地点
1
主要终点
Overall Peak-to-Peak(PtP) N2/P2-component Amplitude of Laser (Somatosensory/Radiant Heat) Evoked Potentials (LEP) in Ultraviolet B (UVB) -Irradiated Skin

研究概览

简要总结

  • To investigate the influence of different doses of BI 1026706 on the primary endpoint (PtP-amplitude LEP in UV skin) compared to placebo.
  • The comparison of both doses of BI 1026706 to celecoxib in the UVB treatment.
  • Comparison of both doses of BI 1026706 to placebo and pregabalin in the capsaicin treatment
  • Exploration of the pharmacokinetics of BI 1026706
  • Exploration of safety and tolerability of BI 1026706

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Test Treatment 2: BI 1026706

Experimental

BI 1026706 and placebo tablet

干预措施: Placebo to BI 1026706 (Drug)

Test Treatment 1: BI 1026706

Experimental

BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet

干预措施: Placebo to BI 1026706 (Drug)

Test Treatment 1: BI 1026706

Experimental

BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet

干预措施: BI 1026706 (Drug)

Test Treatment 2: BI 1026706

Experimental

BI 1026706 and placebo tablet

干预措施: BI 1026706 (Drug)

Reference Treatment 1: BI 1026706

Experimental

Matching placebo to BI 1026706 PfOS and placebo tablet

干预措施: Placebo to BI 1026706 (Drug)

Reference Treatment 2: Celecoxib

Experimental

Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS

干预措施: Placebo to BI 1026706 (Drug)

Reference Treatment 2: Celecoxib

Experimental

Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS

干预措施: Celecoxib (Drug)

Reference Treatment 3: Pregabalin

Experimental

Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS

干预措施: Placebo to BI 1026706 (Drug)

Reference Treatment 3: Pregabalin

Experimental

Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS

干预措施: Pregabalin (Drug)

结局指标

主要结局

Overall Peak-to-Peak(PtP) N2/P2-component Amplitude of Laser (Somatosensory/Radiant Heat) Evoked Potentials (LEP) in Ultraviolet B (UVB) -Irradiated Skin

时间窗: up to 24 hours (h): -2:05h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min])

Overall Peak-to-Peak (PtP) N2/P2-component amplitude of Laser (somatosensory/radiant heat) evoked potentials (LEP) in UVB-irradiated skin. Treated set (TS)

次要结局

  • Electronic Visual Analogue Scale (VAS) (100mm VAS "Post Laser Pain" Scales) - Measured in the UVB-irradiated Skin Type(up to 24 hours(h): -2:05h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min]))
  • Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of (LEP) in Capsaicin-irritated Skin(up to 24 hours(h): -1:20h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min]))
  • Single "Peripheral" N2-component Amplitudes - Measured in Capsaicin-irritated Skin Type(up to 24 hours(h): -1:20h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min]))
  • Single "Central" P2-component Amplitudes - Measured in Capsaicin-irritated Skin Type(up to 24 hours(h): -1:20h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min]))
  • Weighted Needle (Pain) Threshold (WNT) in the Secondary Flare Area of Capsaicin-irritated Skin(up to 24 hours(h): -1:20h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min]))
  • Single "Central" P2-component Amplitudes - Measured in UVB-irradiated Skin Type(up to 24 hours(h): -2:05h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min]))
  • Electronic Visual Analogue Scale (100mm VAS "Post Laser Pain" Scales) - Measured in the Capsaicin-irritated Skin Type.(up to 24 hours(h): -1:20h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min]))
  • Single "Peripheral" N2-component Amplitudes - Measured in UVB-irradiated Skin Type(up to 24 hours(h): -2:05h, 0:30h, 1:00h, 2:00h, 3:00h, 4:00h, 5:00h, 6:00h, 22:00h, 24:00h (relative to study drug administration [h:min]))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验